QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Mural Oncology (NASDAQ:MURA) reported quarterly losses of $(1.77) per share which missed the analyst consensus estimate of $(1....

 mural-oncology-shares-surge-as-company-explores-strategic-alternatives-whats-going-on

Shares of Mural Oncology plc (NASDAQ: MURA) are soaring Monday following the company's announcement that it will discontinu...

Core News & Articles

HC Wainwright & Co. analyst Andres Maldonado maintains Mural Oncology (NASDAQ:MURA) with a Buy and lowers the price targ...

 mural-oncologys-ovarian-cancer-combo-drug-trial-disappoints-stock-plunges

Mural Oncology ends nemvaleukin development for ovarian cancer after ARTISTRY-7 trial misses survival goals. Phase 2 trials for...

Core News & Articles

Jones Trading analyst Soumit Roy downgrades Mural Oncology (NASDAQ:MURA) from Buy to Hold.

Core News & Articles

In the pre-specified interim analysis conducted by the independent data monitoring committee, nemvaleukin in combination with p...

Core News & Articles

HC Wainwright & Co. analyst Andres Maldonado reiterates Mural Oncology (NASDAQ:MURA) with a Buy and maintains $18 price ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION